// App-Quantinova.ai

TPS7576 : A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).

Researchers

Presenter

  • Philippe Armand

Principal Investigators

  • Joshua Brody

  • Paul M. Barr

  • Andrei R. Shustov

  • Alison J. Moskowitz

  • Justin Paul Kline

  • Kerry J. Savage

  • John Kuruvilla

  • Neil C. Josephson

  • Pier Luigi Zinzani

  • Gilles A. Salles

  • Aisha Masood

  • Stephen Maxted Ansell

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Rochester Medcal Center, Rochester, NY

  • University of Washington School of Medicine, Seattle, WA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Chicago Medical Center, Chicago, IL

  • British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Seattle Genetics, Bothell, WA

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Hospices Civils de Lyon, Universite Lyon-1, Lyon, France

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

Locations

  • United States

  • Canada

  • France

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral T-cell lymphoma

  • Cutaneous T-cell lymphoma

  • Hodgkin's Lymphoma

  • Mycosis fungoides

  • Sezary syndrome

  • T-cell lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Solid malignancies

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

  • Nivolumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • I/II

Study Id's

  • NCT02581631

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved